Regulation and activation of p53 and its family members

Cell Death and Differentiation

Volumn 6, Issue 12, 1999, Pages 1162-1168

  Lohrum, M A E ^a   Vousden, K H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

E2F 1; MDM2; p53; p63; p73; Protein stability

Indexed keywords

PROTEIN MDM2; PROTEIN P53; PROTEIN P63; PROTEIN P73; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; STRESS;

EID: 0033381054     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400625     Document Type: Review

References (115)

1. Fu L, Minden MD and Benchimol S (1996) Translational regulation of human p53 gene expression. EMBO J. 15: 4392-4401
2. Hupp TR and Lane DP (1994) Allosteric activation of latent p53 tetramers. Curr. Biol. 4: 865-875
3. Maltzman W and Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol. 4: 1689-1694
4. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51: 6304-6311
5. Maki CG, Huibregtse J and Howley PM (1996) In vivo ubiquitination and proteosome-mediated degradation of p53. Cancer Res. 56: 2649-2654
6. Chowdary DR, Dermody JJ, Jha KK and Ozer HL (1994) Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14: 1997-2003
7. Kubbutat MHG and Vousden KH (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell. Biol. 17: 460-468
8. Pariat M, Carillo S, Molinari M, Salvat C, Debussche L, Bracco L, Milner J and Piechaczyk M (1997) Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol. 17: 2806-2815
9. Zhang W, Lu Q, Xie Z-J and Mellgren RL (1997) Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Try diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. Oncogene 14: 255-263
10. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
11. Kubbutat MHG, Jones SN and Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387: 299-303
12. Haupt Y, Maya R, Kazaz A and Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299
13. Midgley CA and Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189
14. Barak Y, Juven T, Haffner R and Oren M (1993) Mdm-2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468
15. Wu XW, Bayle JH, Olson D and Levine AJ (1993) The p53 mdm-2 autoregulatory feedback loop. Genes and Dev. 7: 1126-1132
16. Marston NJ, Crook T and Vousden KH (1994) Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 9: 2707-2716
17. Reinke V and Lozano G (1997) The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15: 1527-1534
18. Momand J, Zambetti GP, George DL and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
19. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW and Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857-860
20. Haupt Y, Barak Y and Oren M (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15: 1596-1606
21. Chen J, Wu X, Lin J and Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol. Cell. Biol. 16: 2445-2452
22. Jones SN, Roe AE, Donehower LA and Bradley A (1995) Rescue of embyonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208
23. Montes de Oca Luna R, Wagner DS and Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206
24. Böttger A, Böttger V, Sparks A, W-LL, Howard SF and Lane DP (1997) Design of a synthetic Mdm-2 binding mini protein that activates the p53 response in vivo. Current Biology. 7: 860-869
25. Blaydes JP and Wynford-Thomas D (1998) The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 16: 3317-3322
26. Honda R, Tanaka H and Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420: 25-27
27. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18: 22-27
28. Fang S, Jensen JP, Ludwig RL, Vousden KH and Weissman AM (1999) Ubiquitin protein ligase activity of mdm2: Differential RING finger requirements for ubiquitination and proteasomal targeting of mdm2 and p53. Unpublished
29. Hershko A and Ciechanover A (1998) The ubiquitin system. Annu. Rev. Biochem. 67: 425-479
30. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S and Weissman AM (1999) RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96: 11364-11369
31. Roth J, Dobbelstein M, Freedman DA, Shenk T and Levine AJ (1998) Nucleocytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554-564
32. Freedman DA and Levine AJ (1998) Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18: 7288-7293
33. Lain S, Midgley C, Sparks A, Lane EB and Lane DP (1999) An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODS. Exp. Cell. Res. 248: 457-472
34. Tao W and Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. USA 96: 3077-3080
35. ARF stabilizes p53 by blocking nucleocytoplasmic shuttling of Mdm2. Proc. Natl. Acad. Sci. U.S.A. 96: 6937-6941
36. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ and Wahl GM (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J. 18: 1660-1672
37. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS and Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89: 1175-1184
38. Gu W, Shi X-L and Roeder RG (1997) Synergistic activation of transcription by CBP and p53. Nature 387: 819-823
39. Lill NL, Grossman SR, Ginsberg D, DeCaprio J and Livingston DM (1997) Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827
40. Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL and Halazonetis TD (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 57: 3693-3696
41. Thomas A and White E (1998) Suppression of the p300-dependent mdm2 negative-feedback loop induced the p53 apoptotic function. Genes and Dev. 12: 1975-1985
42. Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, Kumar S, Howley PM and Livingston DM (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell. 2: 405-415
43. Jost CA, Marin MC and Kaelin Jr WG (1997) p73 is a human p53-related protein that can induce apoptosis. Nature 389: 191-194
44. Zhu J, Jiang J, Zhou W and Chen X (1998) The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58: 5061-5065
45. Di Como CJ, Gaiddon C and Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19: 1438-1449
46. Lee C-W and La Thangue NB (1999) Promotor specificity and stability control of the p53-related protein p73. Oncogene 18: 4171-4181
47. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WGJ, Oren M, Chen J and Lu H (1999) MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 19: 3257-3266
48. Balint E and Vousden KH (1999) Mdm2 binds p73α without targeting degradation. Oncogene 18: 3923-3929
49. Dobbelstein M, Wienzek S, Koenig S and Roth J (1999) Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18: 2101-2106
50. Ongkeko WM, Wang XQ, Siu WY, Lau AWS, Yamashita K, Harris AL, Cox LS and Poon RYC (1999) MDM2 and MDMX bind and stabilize the p53-related protein p73. Current Biology 9: 829-832
51. Kubbutat MHG, Ludwig RL, Ashcroft M and Vousden KH (1998) Regulation of Mdm2 directed degradation by the C-terminus of p53. Mol. Cell. Biol. 18: 5690-5698
52. Meek DW (1998) Multisite phosphorylation and the integration of stress signals at p53. Cell Signal. 10: 159-166
53. Jayaraman L and Prives C (1999) Covalent and noncovalent modifiers of the p53 protein. Cell. Mol. Life Sci. 55: 76-87
54. Shieh S-Y, Ikeda M, Taya Y and Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334
55. Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt Sionov R, Lozano G, Oren M and Haupt Y (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J. 18: 1805-1814
56. Fuchs SY, Adler V, Pincus MR and Ronai Z (1998) MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA 95: 10541-10546
57. Böttger V, Böttger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG and Lane DP (1999) Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189-199
58. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ and Pavletich NP (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953
59. Ashcroft M, Kubbutat MH and Vousden KH (1999) Regulation of p53 function and stability by phosphorylation. Mol. Cell. Biol. 19: 1751-1758
60. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ and Herrlich P (1999) DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18: 1723-1732
61. Ashcroft M and Vousden KH (1999) Regulation of p53 stability. Oncogene In press
62. Barak Y and Oren M (1992) Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated growth arrest. EMBO J. 11: 2115-2121
63. Mayo LD, Turchi JJ and Berberich SJ (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 57: 5013-5016
64. Guerra B, Gotz C, Wagner P, Montenarh M and Issinger OG (1997) The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. Oncogene 14: 2683-2688
65. Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
66. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE and Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
67. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
68. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ and Sidransky D (1995) A novel p16INK4A transcript. Cancer Res. 55: 2995-2997
69. Duro D, Bernard O, Della Valle V, Berger R and Larsen C-J (1995) A new type of p16/INK4a/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 11: 21-29
70. Quelle DE, Zindy F, Ashmun RA and Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capapble of inducing cell cycle arrest. Cell 83: 993-1000
71. Foulkes WD, Flanders TY, Pollock PM and Hayward NK (1997) The CDK2A (p16) gene and human cancer. Mol. Med. 3: 5-20
72. Ruas M and Peters G (1998) The p16INK4a tumor suppressor and its relatives. Biochim. Biophys. Acta 1378: F115-F177
73. ARF. Cell 91: 649-659
74. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17: 5001-5014
75. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sherr CJ (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95: 8292-8297
76. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
77. Zhang Y, Xiong Y and Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734
78. Zhang Y and Xiong Y (1999) Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of Mdm2 and p53. Mol. Cell. 3: 579-591
79. Weber JD, Taylor LJ, Roussel MF, Sherr CJ and Bar-Sagi D (1999) Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biol. 1: 20-26
80. Hall M and Peters G (1996) Genetic alteraions of cyclins, cyclin dependent kinases and cdk inhibitors in human cancers. Adv. Cancer Res. 68: 67-108
81. Nevins JR (1998) Towards an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth & Diff. 9: 585-593
82. ARF links the tumour suppressors RB and p53. Nature 395: 124-125
83. de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ and Lowe SW (1998) E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 12: 2434-2442
84. Palmero I, Pantoja C and Serrano M (1998) p19ARF links the tumour suppressor p53 to Ras. Nature 395: 125-126
85. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ and Roussel MF (1998) Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433
86. Radfar A, Unnikrishnan I, Lee HW, DePinho RA and Rosenberg N (1998) p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. U.S.A. 95: 13194-13199
87. Hateboer G, Kerkhoven RM, Shvarts A, Bernards R and Beijersbergen RL (1996) Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins. Genes Dev. 10: 2960-2970
88. Martin K, Trouche D, Hagemeier C, Sorensen TS, La Thangue NB and Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694
89. Blattner C, Sparks A and Lane D (1999) Transcription factor E2F-1 is upregulated in response to DNA damage in a manner analogous to that of p53. Mol. Cell. Biol. 19: 3704-3713
90. Hickman ES, Bates Sand Vousden KH (1997) Perturbation of the p53 response by human papillomavirus type 16 E7. J. Virol. 71: 3710-3718
91. Seavey SE, Holubar M, Saucedo LJ and Perry ME (1999) The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19ARF. J. Virol. 73: 7590-7598
92. Phillips AC, Bates S, Ryan KM, Helin K and Vousden KH (1997) Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes and Dev. 11: 1853-1863
93. Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X (1997) E2F-1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes and Dev. 11: 1840-1852
94. Phillips AC, Ernst MK, Bates S, Rice NR and Vousden KH (1999) E2F-1 potentiates cell death by blocking anti-apoptotic signaling pathways. Mol. Cell. 4: 771-781
95. Kaelin WGJ (1999) The emerging p53 gene family. J. Natl. Cancer Inst. 91: 594-598
96. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D and McKeon F. (1998). p63, a p53 homolog at 3q27-29 encodes multiple products with transactivation death-inducing and dominant-negative activites. Mol Cell 2: 305-316.
97. Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M and Haupt Y (1999) c-Abl neutralizes the inhibitory effect of Mdm2 on p53. J. Biol. Chem. 274: 8371-8374
98. Hsieh JK, Chan FS, O'Connor DJ, Mittnacht S, Zhong S and Lu X (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3: 181-193
99. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Fernando J, Leal M, Zhurinsky J, Geiger B and Oren M (1999) Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18: 3054-3063
100. Moll UM, LaQuaglia M, Benard J and Riou G (1995) Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92: 4407-4411
101. Zaika A, Marchenko N and Moll UM (1999) Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J. Biol. Chem. 274: 27474-27480
102. waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory loop. Oncogene 18: 1081-1091
103. Wu L and Levine AJ (1997) Differential Regulation of the p21/WAF-1 and mdm2 genes after high dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Mol. Med. 3: 441-451
104. Fuchs SY, Dolan L, Davis RJ and Ronai Z (1996) Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 8: 1531-1535
105. Fuchs SY, Xie B, Adler V, Fried VA, Davis RJ and Ronai Z (1997) c-Jun NH2-terminal kinases target the ubiquitination of their associated transcription factors. J. Biol. Chem. 272: 32163-32168
106. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai Z (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes and Dev. 12: 2658-2663
107. Gong JG, Costanzo A, Yang H-Q, Melino G, Kaelin WG, Levrero M and Wang JYJ (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplation-induced DNA damage. Nature 399: 806-809
108. Agami R, Blandino G, Oren M and Shaul Y (1999) Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399: 809-813
109. Yuan Z-M, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R and Kufe D (1999) p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399: 814-817
110. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore D, Wynshow-Boris A, Kastan MB and Wang JY (1997) Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 387: 516-519
111. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D and Lavin M (1997) Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387: 520-523
112. Yuan Z-M, Huang Y, Whang Y, Sawyers C, Weichselbaum R, Kharbanda S and Kufe D (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382: 272-274
113. White E and Prives C (1999) DNA damage enables p73. Nature 399: 734-737
114. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C and McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398: 714-717
115. Mills AA, Zheng B, Wang X-J, Vogel H, Roop DR and Bradley A (1999) p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398: 708-713